Jeanin E. van Hooft, MD, PhD Gastroenterologist Academic Medical Centre

Post on 19-Jan-2016

69 views 1 download

Tags:

description

Annual meeting of Colonic Stent Safe Procedure Research Group May 2014 17th, Fukuoka, Japan. Colonic stenting anno 2014. Jeanin E. van Hooft, MD, PhD Gastroenterologist Academic Medical Centre Dept. of Gastroenterology and Hepatology Amsterdam, Netherlands. Colonic stenting anno 2014. - PowerPoint PPT Presentation

Transcript of Jeanin E. van Hooft, MD, PhD Gastroenterologist Academic Medical Centre

Jeanin E. van Hooft, MD, PhDGastroenterologist

Academic Medical CentreDept. of Gastroenterology and Hepatology

Amsterdam, Netherlands

Annual meeting of Colonic Stent Safe Procedure Annual meeting of Colonic Stent Safe Procedure Research Group Research Group

May 2014 17th, Fukuoka, JapanMay 2014 17th, Fukuoka, Japan

Colonic stenting Colonic stenting anno 2014anno 2014

• Introduction• General considerations• Technical considerations • Indications

– Palliation– Bridge to surgery

• Oncological impact• Adverse events • Take home

Colonic stenting anno 2014Colonic stenting anno 2014

• Contraindication for colonic stenting:– Absolute:

• Suspicion of perforation

– Relative• Lack of obstructive symptoms• Peritoneal carcinomatosis • Tumors close to the anal verge ( < 5 cm)

General considerationsGeneral considerationsColonic stenting anno 2014

ESGE clinical guideline on SEMS for obstructing colonic cancer, Van Hooft et al., Endoscopy submitted

• Type of stent – Covered vs uncovered

• Clinical and overall complications equal– Ingrowth 0.9% vs 11.4% and migration 21.3% vs 5.5%

– Diameter• < 24 mm associated with the occurrence of

complications

Technical considerationsTechnical considerationsColonic stenting anno 2014

Zhang et al., Colorectal Dis 2012 Yang et al., Int J Med Sci 2013 Kim et al., J Dig Dis 2012 Manes et al., Arch Surg 2011 Small et al., Gastrointest Endosc 2010Im et al., Colorectal Dis 2008

• Type of stent – Length

• No difference in outcome

– Design• No difference in outcome

Technical considerationsTechnical considerationsColonic stenting anno 2014

Yoon et al., Gastrointest Endosc 2011Selinger et al., Int J Colorectal dis 2011Abbott et al., Br J Surg 2014Geraghty et al., Colorectal dis 2014

New data on palliationNew data on palliationColonic stenting anno 2014

• Summary

New data on palliationNew data on palliationColonic stenting anno 2014

“There is no proven advantage with regard to overall mortality and morbidity and data on effectiveness are contradictious, but SEMS do have some specific advantages (shorter hospital stay, less stoma creation etc.) for palliation of incurable CRC”

New data on bridgeNew data on bridgeColonic stenting anno 2014

• Summary

New data on bridgeNew data on bridgeColonic stenting anno 2014

“Colorectal stenting is as safe as emergency surgery with regard to mortality and appears to have a more favorable overall complication profile and decreases the permanent stoma rate ”

Oncological impactOncological impactColonic stenting anno 2014

Oncological impactOncological impactColonic stenting anno 2014

• Summary

In the palliative setting chemotherapeutics do increase survival but at the expenses of reintervention

In the curative setting SEMS might impairsurvival and increase (local) recurrence

• SEMS for malignant colonic obstruction– Early adverse events (≤ 30 days)

• Perforation 0-12.8%• Stent failure 0-11.7%• Pain 0-7.4%• Stent migration 0-4.9%• Reobstruction 0-4.9%• Bleeding 0-3.7%

Adverse eventsAdverse eventsColonic stenting anno 2014

ESGE clinical guideline on SEMS for obstructing colonic cancer, Van Hooft et al., Endoscopy submitted

• SEMS for malignant colonic obstruction– Late adverse events (≥ 30 days)

• Reobstruction 4-22.9%• Migration 1-12.5%• Perforation 0-4%

Adverse eventsAdverse eventsColonic stenting anno 2014

ESGE clinical guideline on SEMS for obstructing colonic cancer, Van Hooft et al., Endoscopy submitted

• Effect of sum of complications • 30-day mortality <4%• Stent patency

– Palliation Median 160 d (68-288 d)80% (53-90%) until

death– Bridge Large majority

Adverse eventsAdverse eventsColonic stenting anno 2014

ESGE clinical guideline on SEMS for obstructing colonic cancer, Van Hooft et al., Endoscopy submitted

• Introduction• General considerations• Technical considerations • Indications

– Palliation– Bridge to surgery

• Oncological impact• Adverse events • Take home

Colonic stenting anno 2014Colonic stenting anno 2014

• General considerations– Contraindication for colonic stenting– Primary diagnostic tool– Pathological conformation– Preparation of obstructed patients– The operator

• Technical considerations– Stent placement technique– Type of stent

SummarySummaryColonic stenting anno 2014

• Palliation– No proven advantage regarding overall mortality

and morbidity – Data on effectiveness contradictious– Clear advantage regarding

• Hospital stay, stoma formation, time to chemotherapy

– Oncological impact (chemotherapy)• Better survival

• More reinterventions

SummarySummaryColonic stenting anno 2014

• Bridge – No proven advantage regarding overall

mortality – More favorable overall complication profiles– Decrease permanent stoma rate – Oncological impact

• Might impair survival • Increase (local) recurrence

SummarySummaryColonic stenting anno 2014